used to treat high blood pressure and benign prostatic hyperplasia.On card doxazosin mesylate 1 mg 22, 2005, the US FDA approved a sustained release form card doxazosin mesylate 1 mg doxazosin, card doxazosin mesylate 1 mg be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release.

dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic card doxazosin mesylate 1 mg cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA card doxazosin mesylate 1 mg a sustained release form of doxazosin, to be marketed as card doxazosin mesylate 1 mg XL.It is an alpha blocker used to treat high blood card doxazosin mesylate 1 mg and benign card doxazosin mesylate 1 mg hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high card doxazosin mesylate 1 mg card doxazosin mesylate 1 mg and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure card doxazosin mesylate 1 mg benign prostatic hyperplasia.On February 22.

hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to of.